Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Saketh Guntupalli

Concepts (296)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
22
2025
205
4.810
 Why?
Ovarian Neoplasms
17
2026
595
3.050
 Why?
Genital Neoplasms, Female
7
2024
99
2.690
 Why?
Gynecology
8
2021
181
2.370
 Why?
Pyridones
5
2026
209
2.160
 Why?
Enoxaparin
4
2024
68
2.140
 Why?
Carcinoma, Endometrioid
11
2023
49
2.040
 Why?
Hysterectomy
11
2020
138
1.880
 Why?
Pyrazoles
4
2024
517
1.690
 Why?
Uterine Cervical Neoplasms
8
2021
268
1.610
 Why?
Fellowships and Scholarships
5
2018
354
1.600
 Why?
Obstetrics
4
2020
177
1.550
 Why?
Neoplasm Recurrence, Local
11
2026
1149
1.340
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
5
2025
133
1.310
 Why?
Venous Thromboembolism
4
2024
328
1.300
 Why?
Internship and Residency
6
2020
1267
1.280
 Why?
Postoperative Complications
8
2024
2970
1.140
 Why?
Anticoagulants
4
2024
748
1.120
 Why?
Sexual Dysfunction, Physiological
2
2020
75
1.060
 Why?
Lymph Nodes
3
2017
503
1.030
 Why?
Clinical Competence
5
2020
1243
0.960
 Why?
Neoplasm Staging
19
2025
1471
0.840
 Why?
Uterine Neoplasms
3
2021
98
0.780
 Why?
Middle Aged
46
2026
36215
0.700
 Why?
Female
66
2026
78844
0.700
 Why?
Antineoplastic Combined Chemotherapy Protocols
8
2025
1963
0.700
 Why?
Treatment Adherence and Compliance
1
2021
27
0.680
 Why?
Indoles
1
2025
507
0.670
 Why?
Aged
36
2026
26153
0.650
 Why?
Pulmonary Embolism
1
2023
241
0.650
 Why?
Education, Medical, Graduate
2
2016
562
0.640
 Why?
Carcinosarcoma
3
2017
23
0.630
 Why?
Intrauterine Devices
1
2019
29
0.600
 Why?
Robotic Surgical Procedures
3
2016
185
0.560
 Why?
Ovariectomy
4
2015
166
0.550
 Why?
Aged, 80 and over
16
2025
8333
0.550
 Why?
Laparotomy
2
2015
113
0.550
 Why?
Venous Thrombosis
1
2020
196
0.540
 Why?
Humans
69
2026
145474
0.540
 Why?
Oncologists
1
2018
47
0.530
 Why?
Healthcare Disparities
3
2021
735
0.520
 Why?
Quality of Health Care
2
2021
692
0.510
 Why?
Neoplasm Invasiveness
6
2021
506
0.500
 Why?
Prognosis
12
2025
4316
0.500
 Why?
Sexual Dysfunctions, Psychological
1
2017
30
0.500
 Why?
Neoplasms
6
2024
2906
0.490
 Why?
Attitude
1
2018
259
0.480
 Why?
Minority Groups
1
2018
284
0.480
 Why?
Retrospective Studies
17
2024
17291
0.470
 Why?
Medication Adherence
1
2020
540
0.460
 Why?
Gynecologic Surgical Procedures
3
2024
67
0.460
 Why?
Endometrium
2
2019
64
0.440
 Why?
Radiography, Thoracic
1
2016
172
0.430
 Why?
Hemostasis, Surgical
1
2014
25
0.420
 Why?
Abdominal Abscess
1
2014
26
0.420
 Why?
Gelatin
1
2014
56
0.410
 Why?
Surgeons
1
2018
340
0.400
 Why?
Interpersonal Relations
1
2017
397
0.400
 Why?
Adult
30
2026
40777
0.390
 Why?
Thrombin
1
2014
172
0.390
 Why?
WT1 Proteins
1
2013
12
0.380
 Why?
Robotics
1
2014
90
0.380
 Why?
Estrogen Receptor beta
1
2013
40
0.370
 Why?
Histone-Lysine N-Methyltransferase
2
2024
141
0.370
 Why?
Disease-Free Survival
7
2025
767
0.350
 Why?
Follow-Up Studies
9
2024
5423
0.350
 Why?
Adenocarcinoma
3
2021
925
0.350
 Why?
Biomarkers, Tumor
5
2026
1321
0.340
 Why?
Lymphatic Vessels
1
2011
63
0.330
 Why?
Adenocarcinoma, Clear Cell
2
2023
14
0.330
 Why?
Neoplasm Grading
8
2026
310
0.310
 Why?
Smooth Muscle Tumor
1
2009
6
0.300
 Why?
Lymph Node Excision
3
2017
173
0.290
 Why?
Preoperative Care
3
2017
380
0.290
 Why?
Leiomyosarcoma
1
2009
29
0.290
 Why?
Chemotherapy, Adjuvant
4
2025
423
0.290
 Why?
Sarcoma, Alveolar Soft Part
1
2008
6
0.280
 Why?
United States
14
2024
16098
0.260
 Why?
Survival Rate
6
2021
2090
0.260
 Why?
Neoplasms, Second Primary
2
2019
102
0.260
 Why?
Radiotherapy, Adjuvant
3
2018
222
0.250
 Why?
Combined Modality Therapy
3
2020
1266
0.250
 Why?
Insurance, Health
3
2018
310
0.230
 Why?
Peritoneum
1
2025
43
0.230
 Why?
Maintenance Chemotherapy
1
2025
42
0.230
 Why?
Cross-Sectional Studies
5
2017
5904
0.220
 Why?
Risk Factors
7
2024
10885
0.220
 Why?
Insurance Coverage
2
2018
244
0.220
 Why?
Cohort Studies
5
2021
6013
0.220
 Why?
Pregnancy Complications
2
2014
602
0.220
 Why?
Pyrimidinones
1
2026
125
0.220
 Why?
Paclitaxel
6
2024
257
0.220
 Why?
Cystadenocarcinoma, Serous
1
2026
89
0.220
 Why?
Young Adult
7
2021
14218
0.210
 Why?
Lymphatic Metastasis
2
2019
331
0.210
 Why?
Databases, Factual
3
2021
1490
0.210
 Why?
Doxorubicin
2
2024
401
0.200
 Why?
Nomograms
2
2021
59
0.200
 Why?
Self Report
2
2018
870
0.200
 Why?
Chemoradiotherapy
1
2024
239
0.190
 Why?
Immunoglobulin M
1
2024
265
0.190
 Why?
Tertiary Care Centers
1
2023
195
0.180
 Why?
Lung Neoplasms
1
2016
2664
0.180
 Why?
Liver Diseases
1
2005
305
0.180
 Why?
Program Evaluation
2
2018
943
0.180
 Why?
Factor Xa Inhibitors
1
2024
194
0.180
 Why?
Organ Sparing Treatments
2
2019
37
0.180
 Why?
Platinum
1
2022
48
0.180
 Why?
Enzyme-Linked Immunosorbent Assay
1
2024
848
0.180
 Why?
Drug Resistance, Neoplasm
2
2024
881
0.180
 Why?
Adolescent
6
2021
22529
0.170
 Why?
Immunohistochemistry
2
2023
1716
0.170
 Why?
Quality of Life
4
2024
3204
0.170
 Why?
Length of Stay
3
2015
1349
0.170
 Why?
beta Catenin
2
2023
254
0.170
 Why?
BRCA2 Protein
1
2021
68
0.160
 Why?
BRCA1 Protein
1
2021
82
0.160
 Why?
Ovary
2
2019
233
0.160
 Why?
Double-Blind Method
1
2025
2062
0.160
 Why?
High-Throughput Nucleotide Sequencing
1
2023
530
0.160
 Why?
Risk Assessment
4
2024
3747
0.150
 Why?
Fallopian Tube Neoplasms
1
2019
19
0.150
 Why?
Immunoglobulin G
1
2024
892
0.150
 Why?
Cytoreduction Surgical Procedures
1
2020
69
0.150
 Why?
Withholding Treatment
1
2020
80
0.150
 Why?
Treatment Outcome
5
2020
11772
0.150
 Why?
NM23 Nucleoside Diphosphate Kinases
1
2019
2
0.150
 Why?
Postoperative Hemorrhage
1
2020
105
0.150
 Why?
Polyethylene Glycols
1
2024
649
0.140
 Why?
Age Factors
4
2016
3342
0.140
 Why?
Peritoneal Neoplasms
1
2019
104
0.140
 Why?
Cisplatin
4
2024
345
0.140
 Why?
Incidence
3
2024
2923
0.140
 Why?
CD8-Positive T-Lymphocytes
1
2024
919
0.140
 Why?
Pregnancy
4
2020
7202
0.140
 Why?
Mutation
3
2026
4075
0.130
 Why?
Fibrinolytic Agents
1
2020
297
0.130
 Why?
Stathmin
1
2017
2
0.130
 Why?
Carcinoma, Adenosquamous
1
2017
9
0.130
 Why?
Cancer Survivors
1
2023
337
0.130
 Why?
Carboplatin
3
2024
162
0.130
 Why?
Carcinoma
1
2019
225
0.130
 Why?
Randomized Controlled Trials as Topic
2
2021
1747
0.130
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2017
27
0.130
 Why?
Blood Loss, Surgical
2
2015
113
0.120
 Why?
Guideline Adherence
1
2021
586
0.120
 Why?
Neoadjuvant Therapy
1
2020
465
0.120
 Why?
Socioeconomic Factors
1
2021
1323
0.120
 Why?
Societies, Medical
1
2021
899
0.120
 Why?
National Cancer Institute (U.S.)
1
2016
54
0.120
 Why?
Case-Control Studies
4
2019
3623
0.120
 Why?
Carcinoma, Squamous Cell
2
2021
641
0.120
 Why?
Health Status Disparities
2
2017
321
0.120
 Why?
Uterus
2
2023
227
0.120
 Why?
Benzamides
1
2017
226
0.120
 Why?
Surgical Oncology
1
2016
30
0.120
 Why?
Neonatology
1
2016
32
0.120
 Why?
Reimbursement Mechanisms
1
2016
79
0.120
 Why?
Marriage
1
2017
121
0.110
 Why?
Perioperative Care
1
2018
231
0.110
 Why?
Piperidines
1
2017
222
0.110
 Why?
Bevacizumab
3
2021
168
0.110
 Why?
Prospective Studies
7
2025
8057
0.110
 Why?
Drug Costs
1
2016
117
0.110
 Why?
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
2015
22
0.110
 Why?
Pneumonia, Viral
1
2020
389
0.110
 Why?
Coronavirus Infections
1
2020
383
0.110
 Why?
Female Urogenital Diseases
1
2014
7
0.110
 Why?
Pregnancy Complications, Neoplastic
1
2015
63
0.110
 Why?
Morbidity
1
2015
322
0.110
 Why?
Peritoneal Cavity
1
2014
30
0.110
 Why?
Surgical Wound Dehiscence
1
2014
22
0.110
 Why?
Blood Volume
1
2014
65
0.100
 Why?
Intraoperative Complications
1
2015
157
0.100
 Why?
Maternal-Fetal Exchange
1
2015
170
0.100
 Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2017
345
0.100
 Why?
Hemostatics
1
2014
64
0.100
 Why?
Colposcopy
1
2013
18
0.100
 Why?
Drainage
1
2014
185
0.100
 Why?
Health Policy
1
2016
400
0.090
 Why?
Antibodies
1
2015
397
0.090
 Why?
Needs Assessment
1
2015
402
0.090
 Why?
Patient Readmission
1
2018
769
0.090
 Why?
Referral and Consultation
1
2018
867
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
33
0.090
 Why?
DNA Polymerase II
2
2023
35
0.090
 Why?
Pandemics
1
2020
1707
0.080
 Why?
Proportional Hazards Models
3
2021
1327
0.080
 Why?
Clinical Trials as Topic
1
2016
1061
0.080
 Why?
Surgical Wound Infection
1
2014
329
0.080
 Why?
Early Detection of Cancer
1
2016
485
0.080
 Why?
Fetus
1
2015
804
0.080
 Why?
Kaplan-Meier Estimate
1
2013
969
0.080
 Why?
Multivariate Analysis
1
2013
1547
0.070
 Why?
Benzimidazoles
2
2021
189
0.070
 Why?
Metrorrhagia
1
2008
4
0.070
 Why?
Dilatation and Curettage
1
2008
12
0.070
 Why?
Multicenter Studies as Topic
2
2021
412
0.070
 Why?
Pediatrics
1
2016
1121
0.070
 Why?
Surveys and Questionnaires
2
2018
6066
0.070
 Why?
Tumor Suppressor Protein p53
2
2023
534
0.060
 Why?
Male
7
2024
72842
0.060
 Why?
SEER Program
2
2018
229
0.060
 Why?
Quality Improvement
1
2015
1295
0.060
 Why?
Models, Biological
1
2014
1764
0.060
 Why?
Cell Line, Tumor
2
2024
3542
0.060
 Why?
Rupture, Spontaneous
1
2005
15
0.060
 Why?
Budd-Chiari Syndrome
1
2005
5
0.060
 Why?
HELLP Syndrome
1
2005
5
0.060
 Why?
Hepatolenticular Degeneration
1
2005
15
0.060
 Why?
Hematoma
1
2005
63
0.060
 Why?
Hepatitis B
1
2005
66
0.050
 Why?
Histocompatibility Antigens
1
2024
102
0.050
 Why?
Cost-Benefit Analysis
2
2020
639
0.050
 Why?
Colorado
1
2014
4553
0.050
 Why?
Obesity
2
2016
3116
0.050
 Why?
Tomography, X-Ray Computed
1
2014
2769
0.050
 Why?
Anti-Bacterial Agents
1
2014
1923
0.050
 Why?
DNA Mismatch Repair
1
2023
53
0.050
 Why?
Pre-Eclampsia
1
2005
206
0.050
 Why?
Cholestasis
1
2005
214
0.050
 Why?
Fatty Liver
1
2005
253
0.050
 Why?
Hepatitis C
1
2005
256
0.050
 Why?
Decision Support Techniques
2
2020
477
0.050
 Why?
Acute Disease
1
2005
1036
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
14
0.050
 Why?
Medical Futility
1
2022
32
0.050
 Why?
Claudin-4
1
2022
18
0.040
 Why?
Liposomes
1
2024
262
0.040
 Why?
Genes, BRCA2
1
2021
33
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2021
50
0.040
 Why?
Genes, BRCA1
1
2021
45
0.040
 Why?
Xenograft Model Antitumor Assays
1
2024
934
0.040
 Why?
Hematologic Diseases
1
2021
66
0.040
 Why?
Topotecan
1
2020
17
0.040
 Why?
Organoplatinum Compounds
1
2020
65
0.040
 Why?
Quality-Adjusted Life Years
1
2020
123
0.040
 Why?
Life Style
1
2023
485
0.040
 Why?
Injections, Intraperitoneal
1
2019
116
0.040
 Why?
DNA Repair
1
2022
254
0.040
 Why?
Injections, Intravenous
1
2019
197
0.040
 Why?
Critical Care
1
2005
702
0.040
 Why?
Japan
1
2019
149
0.040
 Why?
Platinum Compounds
1
2019
10
0.040
 Why?
DNA Damage
1
2022
437
0.040
 Why?
Infusions, Intravenous
1
2020
428
0.040
 Why?
Microsatellite Instability
1
2019
55
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
108
0.030
 Why?
Angiogenesis Inhibitors
1
2020
238
0.030
 Why?
Gene Expression Regulation, Neoplastic
1
2024
1443
0.030
 Why?
PTEN Phosphohydrolase
1
2019
165
0.030
 Why?
Antineoplastic Agents, Phytogenic
1
2019
178
0.030
 Why?
Survival Analysis
1
2021
1374
0.030
 Why?
Administration, Oral
1
2020
866
0.030
 Why?
Betacoronavirus
1
2020
288
0.030
 Why?
Mice
2
2024
18329
0.030
 Why?
Cell Proliferation
1
2024
2507
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
13
0.030
 Why?
Time Factors
2
2017
7123
0.030
 Why?
Hospitals, Teaching
1
2016
120
0.030
 Why?
Social Class
1
2017
264
0.030
 Why?
Odds Ratio
1
2018
1082
0.030
 Why?
ErbB Receptors
1
2019
635
0.030
 Why?
Patient Reported Outcome Measures
1
2020
497
0.030
 Why?
Medically Uninsured
1
2016
132
0.030
 Why?
Dose-Response Relationship, Drug
1
2019
2028
0.030
 Why?
Ileus
1
2015
13
0.030
 Why?
Salpingectomy
1
2015
15
0.030
 Why?
Urinary Retention
1
2015
24
0.030
 Why?
Income
1
2016
202
0.030
 Why?
Diet
1
2023
1277
0.030
 Why?
Advisory Committees
1
2016
229
0.030
 Why?
Elective Surgical Procedures
1
2016
202
0.030
 Why?
Pelvis
1
2015
125
0.030
 Why?
Disease Models, Animal
1
2024
4560
0.020
 Why?
Papanicolaou Test
1
2013
35
0.020
 Why?
Vaginal Smears
1
2013
54
0.020
 Why?
Urban Population
1
2016
493
0.020
 Why?
Critical Pathways
1
2014
109
0.020
 Why?
Clinical Protocols
1
2014
280
0.020
 Why?
Membrane Proteins
1
2019
1164
0.020
 Why?
Animals
2
2024
38030
0.020
 Why?
Pregnancy Outcome
1
2015
503
0.020
 Why?
Polymorphism, Single Nucleotide
1
2019
2158
0.020
 Why?
Comorbidity
1
2016
1661
0.020
 Why?
Disease Progression
1
2019
2864
0.020
 Why?
Rural Population
1
2016
659
0.020
 Why?
Exercise
1
2023
2198
0.020
 Why?
Biomedical Research
1
2016
717
0.020
 Why?
Curriculum
1
2016
1070
0.020
 Why?
Prostatic Neoplasms
1
2016
978
0.020
 Why?
Patient Discharge
1
2015
992
0.020
 Why?
Colorectal Neoplasms
1
2016
866
0.020
 Why?
Infant, Newborn
1
2015
6447
0.010
 Why?
Breast Neoplasms
1
2016
2382
0.010
 Why?
Guntupalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (296) concept(s)
_
Co-Authors Expand Description
See all (34) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)